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Abstract. 
Purpose: The purpose of our study was to evaluate the clinical features and survival of colo-
rectal cancer patients 40 years of age and under. 
Patients and Methods: From January 1, 2007 to December 31, 2012, a total of 819 colorectal 
cancer patients were admitted to our hospital, of which 23 cases (2.8%) were equal to or less 
than 40 years of age. We analyzed their clinical pictures and compared their prognoses to that 
of their colorectal cancer counterparts older than 40 years of age.  
Results: The gender distribution, staging, histological grading, and KRAS mutation rate 
showed no difference between the two groups. Even the incidence of mucinous carcinoma 
with special histology was 8.3% ( in < 40 age group) vs. 3.5% (in > 40 age group), without 
statistical significance ( p = 0.219). Overall, the survival analysis demonstrated there to be no 
difference in each stage between patients 40 years of age and under, and those patients over 40 
years of age. 
Conclusions: There was no difference in the clinical features and survival duration of colo-
rectal cancer patients between those patients less than 40 years of age and those more than 40 
years of age. 
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中文摘要 
目的：評估小於等於 40 歲的大腸直腸癌的臨床表現及存活率。 
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方法：收集本院自 2007 年一月到 2012 年十二月共 819 位大腸直腸癌的病人，其中 23 位
(2.8%)小於等於 40 歲。分析臨床表現及存活率，並與大於 40 歲大腸直腸癌的病患做相關
探討。 
結果：在小於等於 40 歲和大於 40 歲的大腸直腸癌中，在性別、分期、組織學等級、KRAS 
突變率並無差異；甚至在組織學上特殊的黏液性癌方面，小於 40 歲為 8.3% 而大於 40 歲
為 3.5%，但無統計學上意義(p=0.219)。而在存活率分析方面，在同一個期別小於等於 40
歲和大於 40 歲的大腸直腸癌，兩者存活率並無不同。 
結論：無論在臨床表現及存活率，在小於 40 歲或大於 40 歲的大腸直腸癌並無差異。 
 
關鍵字: 大腸直腸癌、小於 40 歲、KRAS 突變 
 
INTRODUCTION 
The incidence of colorectal cancer in Taiwan has 
been increasing in recent years, accounting for more 
than ten thousand deaths annually [1]. With the total 
number of cases also increasing, we are also encoun-
tering a growing tally of younger-aged patients. Most 
studies have recognized under 40 years old as the 
threshold to describe young colorectal cancer victims 
[2,3], although some have suggested a preference for 
30 years of age [4]. Patient survival duration varies 
depending upon the study, and the country’s popula-
tion that is being studied; some investigations suggest 
that young patients have a poor survival duration [2,5], 
while other studies indicate that both young and older 
patients have the same prognosis [4,6]. However, the 
clinical-pathologic features revealed in these studies 
show a greater level of consistency: most studies sug-
gest that colorectal cancer staging is the main prog-
nostic factor [2,4,5]. Furthermore, there appear to be is 
more mucinous adenocarcinoma subtypes as well 
[7,8]. Although KRAS gene mutation is now a routine 
screening test for stage IV colorectal cancer, there is 
limited data available addressing the mutation rate of 
the KRAS gene in the population less than 40 years of 
age [9].  
We collected the colorectal clinical pathologic data 
from our cancer database, to evaluate the differences 
between colorectal cancer patients less than and equal 
to age 40, and those in excess of 40 years of age.  
 
MATERIAL AND METHODS  
We collected our data from a cancer database with 
accompanying chart review under the permission of 
IRB (TCHIRB-1020429-E). Those patients included 
in the study suffered from colorectal cancer and were 
diagnosed and treated in this hospital. From January 
2007 to December 2012, a total of 819 patients were 
deemed eligible for our study. The designated varia-
bles of this study included sex, tumor location (colon 
vs. rectum), staging, cell differentiation grading, spe-
cial mucinous adenocarcinoma cell type, perforation 
and obstruction high risk factor, KRAS Codon 12 or 
Codon 13 mutation status. The staging was assessed 
by AJCC classification based on histological exami-
nation of the resected specimen. 
 
Follow-up 
Each patient’s survival status was evaluated by re-
view of the cancer database. For those study subjects 
who were lost to follow-up for a period in excess of 3 
months, we undertook telephone contact and other 
follow-up for all patients. 
 
Statistical Analysis 
We used Kaplan-Meier survival analysis method 
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for calculation of survival curve, and statistical analy-
sis performed using the Log-Rank test. Comparisons 
of associations between sex and other variables were 
carried out using the Fisher’s exact test. The p value 
was set at 0.05 for statistical significance. 
 
RESULTS 
From January 2007 to December 2012, there were 
891 patients suffering from colorectal cancer who 
were diagnosed and treated at the Taipei City Hospital 
Ren-Ai Branch. Our study is retrospective in nature 
and observational, where patients are grouped accord-
ing to age, resulting in a large variation in number 
between the two groups. When there was a small 
sample size, we used Fisher’s exact test, which is a 
statistic analysis method specific for small sample size 
(Figure 1). Among the two groups, the ratio of male to 
female was 1.3 in the less or equal to age 40 group 
(group 1), and a m/f ratio of 1.26 in the group con-
sisting of men 40 years of age and older (group 2). 
The patients in group 1 had a higher incidence of rec-
tal cancer (11 of 23 cases, 48%) in comparison with 
group 2 (246 of 819, 19%), with a non-significant p 
value of 0.10. The stage distribution from stage 0 to 
stage IV was similar in both groups, where p = 0.09. 
However, there was more stage IV disease in group 1 
(38%) than in group 2 (24%). None of the group one 
patients suffered an obstruction or perforation, while 
there was a 5% obstruction and 12% tumor perforation 
rate in group 2, but without statistical significance. 
Although we subdivided the group 1 and group 2 pa-
tients by pathologic differentiation to compare with 
group 3 and group 4 patients, there was no difference 
between these two groups. Many studies have shown 
Table 1. Characteristics of colorectal cancer grouped by age 
 Colorectal cancer ≦ 40 years old Colorectal cancer ＞ 40 years old p-value
Gender M / F 13/10 444/352 1.00 
Colon 12(52%) 573(70%) 0.10 
Rectal 11(48%) 246(30%)  
subtotal 23(100%) 819(100%)  
Stage   0.10 
0 1(5%) 65(8%)  
I 4(19%) 143(18%)  
II 3(14%) 167(22%)  
III 5(24%) 213(28%)  
IV 8(38%) 188(24%)  
subtotal 21(100%) 776(100%)  
Obstruction 0/23(0%) 8/165(5%) 0.60 
Tumor perforation 0/23(0%) 20/165(12%) 0.14 
Pathologic grading    0.77 
Grade I ~ II 14(78%) 515(80%)  
Grade III ~ IV 4(22%) 125(20%)  
subtotal 18(100%) 640(100%)  
Mucinous adenocarcinoma 2/23(8.7%) 28/796(3.5%) 0.22 
KRAS mutation(12/13) 5/19(26.3%) 104/260(40%) 0.49 
p-value by Fisher’s exact test  
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Figure 1. Stage I overall survival curve and 5-year survival of two groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Stage II overall survival curve and 5-year survival of two groups 
<= 40yr, 5yrs overall survival 100% 
> 40yr, 5yrs overall survival 85.1% 
    Log Rank Test P=0.630
<= 40yr, 5yrs overall survival 100% 
> 40yr, 5yrs overall survival 85.3% 
    Log Rank Test P=0.547
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Figure 3. Stage III overall survival curve and 5-year survival of two groups 
 
 
that the special histology-type mucinous adenocarci-
noma is prone to occur in young patients, and our se-
ries also demonstrated this result: where 8.7% of pa-
tients in group 1 had mucinous adenocarcinoma his-
tology , only 3.5% of the group 2 patients shared the 
same histology , but were not statistically significant. 
(p=0.219). Some of our patients have undergone 
KRAS mutation analysis of their surgical specimen, 
suggesting that the young age group seemed to have 
less codon 12 or codon 13 mutation (26.3%) than the 
older group (40%) (Table 1).  
    
Survival Analysis 
Regarding the survival analysis of these study par-
ticipants, there were 4 patients in group 1 and 143 
patients in group 2 with stage I colorectal cancer, with 
5-year survival rates of 100% and 85.1%, respectively 
(Figure 1). For study participants with stage II disease, 
group 1 had 3 patients and group 2 had 167 patients, 
with 5-year survival rates of 100% and 85.3%, respec-
tively (Figure 2). Regarding those study participants 
with stage III colorectal cancer, group 1 had 5 patients 
and group 2 had 213 patients, with 5-year survival 
rates of 66.7% and 57.4%, respectively (Figure 3). For 
stage IV disease, group 1 had 8 patients and group 2 
had 188 patients, with 2-year survival rates of 45% 
and 49.2%, respectively (Figure 4). Because of the 
small number of group 1 patients, there was not any 
statistically difference in survivorship.  
  
DISCUSSION 
Discovering that a young patient with colorectal 
cancer has a poor prognosis has always been a diffi-
cult medical conclusion to reach for clinicians and 
patients alike. A Denmark study of 951 patients less 
than 40 years of age using epidemiological data from 
1943-1967, which demonstrated no difference in the 
sex ratio, tumor location, extent of tumor growth, his-
tology type, and perforation or obstruction. The author 
concluded that colorectal cancer in young patients  
<= 40yr, 5yrs overall survival 66.7%
> 40yr, 5yrs overall survival 57.4%
    Log Rank Test  P=0.826 
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Figure 4. Stage IV overall survival curve and 2-year survival of two groups 
 
 
does not significantly differ in any respect from the 
disease in older patients [2]. The France group also 
pointed out that their colorectal cancer rates in patients 
less than 40 years of age was 3% (32/1037). There 
also was no difference between different stages and in 
5-year survival [6]. The results were the same in the 
Taiwanese data, when Liang et al. demonstrated alt-
hough more advanced tumour stage were present in 
younger (<40 y/o) rather than older patients (>60 y/o), 
the cancer specific survival was similar in stage I, II, 
III disease, and even better in stage IV disease [10]. 
She et al. also found stage-by-stage analysis which 
revealed that survival in younger patients was not 
different from average-aged patients [4]. Our data 
showed similar results, there were no different in 5 yrs 
survival in group 1 and group 2 patients, although 
there were more stage IV disease in group 1(38%) 
than group 2(24%). Nevertheless, when we pooled 
together all the stage IV patients undergoing phase III 
clinical trial, either USA data or European data, 
demonstrated young age patients had less responsive 
to treatment, causing worse progression free survival 
[6,11], and poorer overall survival [11]. 
Our study did not showed tumor perforation or 
obstruction in 23 cases of less than 40 of age group, 
in contrast to another Taiwanese study [4], which 
showed higher rate of tumor perforation. Most other 
studies didn’t address this point. However, there are 
more special histology type mucinous adenocarcino-
ma happened in young patients than old patients in 
either Caucasian people or Asian people. The inci-
dence involving mucin-producing tumor of the patient 
in our study is 8.7%, comparable to up to 13.8% in 
Caucasian[7] or 14.5% [10], and 26% in Asian [12]. It 
is hard to explain why our series had a lower inci-
dence of mucinous adenocarcinoma, although it still 
reflects higher incidence than the >40 yrs group 
(3.5%), however, the low total number (n=23) in-
<= 40yr, 2yrs overall survival 45% 
> 40yr, 2yrs overall survival 49.2% 
    Log Rank Test  P=0.829 
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cluded for study may be the explanation. 
However, several series studies of Taiwanese pa-
tients did not show any elevated level of rectal cancer 
in young patients (36.2% in Liang’s study [10] and 
24% in Lin’s study [12]). In our study, we have a sub-
stantially higher percentage of rectal cancer in group 1 
(48%) versus group 2 (30%) (p=0.10). This suggests 
that young patients may be more susceptible to rectal 
cancer than their older counterparts. The SEER data 
from Korea also showed a higher incidence of rectal 
cancer rather than colon cancer. The figures for annual 
occurrence per 100,000 people less than 40 years of 
age were colon cancer : rectal cancer = 5.7:5.9 in male, 
and 5.2:6.5 in female patients. As patient age increas-
es, the incidence of colon cancer increases, until fi-
nally the ratio is reversed [13]. 
We performed KRAS genetic testing on speci-
mens from 19 young colorectal cancer patients, and 
compared them with previous KRAS mutation studies 
for patients with advanced colorectal cancer. We 
found the mutation rate of codon 12 and codon 13 in 
this young group (26.3%) was lower than in the older 
group (40%), where p = 0.48. There is data indicating 
that in the early year [9], KRAS mutation occurs less 
frequently in the colonic tumors of male rather than 
female patients, with a total mutation rate 39%. The 
low mutation rate in our series may have been at-
tributable to small sample size. 
 
CONCLUSIONS 
The characteristics of colorectal cancer in patients 
less than 40 years of age in Taipei City Hospital 
Ren-Ai Branch are the same as found in the literature. 
The survival analysis showed no difference in results 
between patients under 40 and those older than 40. 
However, further KRAS study of colorectal cancer 
patients less than 40 years of age is strongly recom-
mended. 
 
REFERENCES 
1. Department of Health, Executive Yuan, R.O.C. 
(Taiwan). Health and Vital Statistics. (http://www. 
mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=3 
12&fod_list_no=2747 ) 
2. Bülow S. Colorectal cancer in patients less than 
40 years of age in Denmark, 1943-1967. Dis Co-
lon Rectum 23: 327-36, 1980. 
3. Robert EF, Tammy LF, Robert M J, et al. Colon 
cancer in patient 40 years old or younger is colon 
rectum. BUMC Proceedings 11: 175-178, 1998. 
4. She KM, Wang HM, Chen JB, et al. Colorectal 
cancer in younger than 30 years old group is not 
associated with poor prognosis. J Soc Colon 
Rectal Surgeon (Taiwan) 22: 93-98, 2011. 
5. Mitry E, Benhamiche AM, Jouve JL, et al. Colo-
rectal adenocarcinoma in patients under 45 years 
of age: comparison with older patients in a 
well-defined French population. Dis Colon Rec-
tum 44: 380-387, 2001. 
6. Charles DB, Brian MB, David MT, et al. Impact 
of young age on treatment efficacy and safety in 
advanced colorectal cancer: a pooled analysis of 
patients from nine first-line phase III chemother-
apy trials. J Clin Oncol 29: 2781-2786, 2011. 
7. Soliman AS, Bondy ML, Levin B, et al. Colorec-
tal cancer in Egyptian patients under 40 years of 
age. Int J Cancer 71: 26-30, 1997. 
8. Adloff M, Arnaud JP, Schloegel M, et al. Colo-
rectal cancer in patients under 40 years of age. Int 
Dis Colon Rectum 29: 322-326, 1986. 
9. Breivik J, Meling GI, Spurkland A, et al. K-ras 
mutation in colorectal cancer: relations to patient 
age, sex and tumour location. Br J Cancer 69: 
367-71, 1944. 
10. Liang JT, Huang KC, Cheng AL, et al. Clinico-
pathological and molecular biological features of 
colorectal cancer in patients less than 40 years of 
age. Br J Surg 90: 205-214, 2003. 
11. Martinelli E. ESMO @ ECC 2013: Younger age 
in patients with metastatic colorectal cancer asso-
ciatees with poorer outcome: An analysis from the 
ARCAD clinical trials programme. (http://www. 
M. C. Lu et al./JCRP 2(2015) 205-212 211
esmo.org/Conferences/Past-Conferences/European- 
Cancer-Congress-2013 ) 
12. Lin JT, Wang WS, Yen CC, et al. Outcome of 
colorectal carcinoma in patients under 40 years of 
age. J Gastroenterol Hepatol 20: 900-905, 2005.  
13. Park HC, Shin A, Kim BW, et al. Data on the 
characteristics and the survival of Korean patients 
with colorectal cancer from the Korea central 
cancer registry. Ann Coloproctol 29: 144-149, 
2013. 
 
212 M. C. Lu et al./JCRP 2(2015) 205-212
